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Purpose
The purpose is to standardized practices in the neurofibromatosis clinic
by establishing clinical guidelines among the healthcare providers,
increasing the productivity of the new patients’ appointment times
through use of an evidence-based checklist (CL). It is crucial to optimize
the patients’ experience by evaluating the complete organ systems of
those affected with NF1 and potentially decreasing clinic wait times. A
new patient checklist can be beneficial to achieve these goals.

Background
Neurofibromatosis 1 (NF1) is a chronic medical condition with clinical
variability in presentation and medical management. The physical
examination is vital in making the clinical diagnosis, further diagnostic
studies, and referrals needed to investigate the extent of the disease
burden (Jett & Friedman, 2010). Due to the disease process’s
complexities, the clinic appointment times may require 60-90 minutes for
annual physical examinations. New patient appointments frequently take
longer than the allotted 60 minutes.

Individualized New Pediatric Patient Checklist for
Neurofibromatosis Type 1

Results
A baseline time study was collected from January through March 2020,
revealing five new NF1 patient clinic visits that took an average of 96 minutes to
complete the visit. The time began once the patient was in the exam room to
start vital signs until the health care provider concluded the visit and the patient
was walking out of the exam room. During the project period, a total of six new
patients evaluated for NF1. The CL utilization in new NF1 patients increased
from baseline of 0% at project implantation to 100% at four months post project
implementation. A total of six CLs was completed from May 2020 through
August 2020, completed by the APP. A time study was completed for the six
CLs completed, with an average of 101.3 minutes for the visits. There was not
an improvement in clinic times.

Conclusion

Aim Statement
This project aims to design a disease-specific CL for pediatric patients
that are being evaluated for a new diagnosis of NF1. The plan is to use
this CL for 95% of all new patient appointment visits within six months of
implementation to standardize the clinical process providing evidencebased care. This CL is evidence-based with typical clinical symptoms of
patients with NF1 with limited options available in the literature.
Additionally, this pilot study should decrease appointment visit times by
30 minutes over three months to improve clinic workflow. Improvements
in wait times could also sustain positive patient satisfaction scores.

Methods
The Plan-Do-Study-Act (PDSA) method of quality of improvement was
used for this project. Author conducted a systematic literature review to
explore literature for the benefits of a checklist in NF1. A CL was designed
using evidence for the needs of the NF1 patient. A baseline 3-month time
study was collected before starting the project, confirming the number of
minutes spent for all new pediatric patient appointments for NF1. The new
patient CL was implemented at each initial visit. The Advanced Practice
Provider (APP) collected time data and completed the new patient CL.

There was a creation and implementation of a disease-specific CL for pediatric
patients evaluated for new diagnosis of NF type 1. The CL did not improve
clinic times. There were multiple variables related to the COVID-19 pandemic,
changes in staffing, and data highlighting clinical variability as a time critical
issue when examining new patients with NF1.

Implications for DNP Practice
CLs allowed for providers to document individualized patient information to
readily identify each patients’- specific disease burden, diagnostic workup
needed for further evaluation, and ongoing needed management. It will also
serve as a personalized, educational tool for families and patients with NF1.
This evidence-based CL is created with common clinical symptoms of patients
with NF1 currently limited in the literature.
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